Associations between ICD-related SNPs and clinical outcomes
| Genotype | N | TR | PFS | OS | |||||||
| ORR (%) | P value* | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||
| HR (95% CI) | P value† | HR (95% CI) | P value‡ | HR (95% CI) | P value† | HR (95% CI) | P value‡ | ||||
| CALR rs1010222 | |||||||||||
| Discovery cohort | |||||||||||
| G/G | 72 | 66.2 | 0.48 | 1 | 0.008 | 1 | 0.10 | 1 | 0.07 | 1 | 0.38 |
| Any A | 87 | 60.7 | 0.61 (0.43 to 0.88) | 0.67 (0.42 to 1.07) | 0.67 (0.44 to 1.04) | 0.78 (0.46 to 1.35) | |||||
| Validation cohort | |||||||||||
| G/G | 44 | 71.4 | 0.33 | 1 | 0.63 | 1 | 0.61 | 1 | 0.76 | 1 | 0.35 |
| Any A | 65 | 62.3 | 0.90 (0.57 to 1.41) | 0.87 (0.52 to 1.46) | 0.93 (0.60 to 1.44) | 0.79 (0.49 to 1.29) | |||||
| Control cohort 1 | |||||||||||
| G/G | 81 | 67.5 | 1.00 | 1 | 0.98 | 1 | 0.88 | 1 | 0.41 | 1 | 0.94 |
| Any A | 82 | 67.5 | 0.99 (0.69 to 1.44) | 0.96 (0.58 to 1.60) | 0.81 (0.49 to 1.34) | 0.97 (0.50 to 1.89) | |||||
| Control cohort 2 | |||||||||||
| G/G | 90 | 63.6 | 0.16 | 1 | 0.37 | 1 | 0.56 | 1 | 0.75 | 1 | 0.79 |
| Any A | 119 | 53.9 | 1.16 (0.84 to 1.58) | 1.11 (0.79 to 1.56) | 1.05 (0.77 to 1.44) | 0.96 (0.69 to 1.33) | |||||
| ANXA1 rs1050305 | |||||||||||
| Discovery cohort | |||||||||||
| A/A | 138 | 63.4 | 0.99 | 1 | 0.26 | 1 | 0.47 | 1 | 0.03 | 1 | 0.10 |
| Any G | 22 | 63.6 | 1.33 (0.81 to 2.21) | 1.29 (0.66 to 2.51) | 1.87 (1.04 to 3.35) | 1.96 (0.93 to 4.12) | |||||
| Validation cohort | |||||||||||
| A/A | 91 | 70.6 | 0.03 | 1 | 0.009 | 1 | 0.17 | 1 | <0.001 | 1 | 0.04 |
| Any G | 18 | 44.4 | 2.17 (1.20 to 3.92) | 1.62 (0.83 to 3.16) | 2.69 (1.56 to 4.61) | 2.00 (1.07 to 3.72) | |||||
| Control cohort 1 | |||||||||||
| A/A | 128 | 66.9 | 0.67 | 1 | 0.72 | 1 | 0.85 | 1 | 0.82 | 1 | 0.63 |
| Any G | 33 | 71.0 | 1.08 (0.70 to 1.67) | 1.07 (0.54 to 2.11) | 1.07 (0.60 to 1.92) | 0.81 (0.33 to 1.98) | |||||
| Control cohort 2 | |||||||||||
| A/A | 184 | 57.6 | 0.70 | 1 | 0.92 | 1 | 0.72 | 1 | 0.23 | 1 | 0.09 |
| Any G | 31 | 61.3 | 1.02 (0.66 to 1.58) | 1.09 (0.68 to 1.74) | 0.76 (0.48 to 1.19) | 0.67 (0.42 to 1.09) | |||||
| LRP1 rs1799986 | |||||||||||
| Discovery cohort | |||||||||||
| C/C | 111 | 64.2 | 0.99 | 1 | 0.22 | 1 | 0.53 | 1 | 0.03 | 1 | 0.14 |
| Any T | 44 | 64.3 | 1.30 (0.85 to 1.97) | 1.18 (0.71 to 1.94) | 1.69 (1.07 to 2.70) | 1.55 (0.87 to 2.74) | |||||
| Validation cohort | |||||||||||
| C/C | 74 | 63.9 | 0.52 | 1 | 0.35 | 1 | 0.005 | 1 | 0.98 | 1 | 0.42 |
| Any T | 24 | 71.4 | 1.30 (0.75 to 2.25) | 2.71 (1.37 to 5.37) | 0.99 (0.58 to 1.71) | 1.30 (0.70 to 2.40) | |||||
| Control cohort 1 | |||||||||||
| C/C | 126 | 65.9 | 0.28 | 1 | 0.35 | 1 | 0.79 | 1 | 0.68 | 1 | 0.38 |
| Any T | 33 | 75.8 | 1.23 (0.79 to 1.92) | 0.93 (0.52 to 1.66) | 1.13 (0.63 to 2.02) | 0.71 (0.33 to 1.53) | |||||
| Control cohort 2 | |||||||||||
| C/C | 162 | 58.9 | 0.45 | 1 | 0.34 | 1 | 0.59 | 1 | 0.57 | 1 | 0.66 |
| Any T | 44 | 52.4 | 0.83 (0.57 to 1.22) | 0.90 (0.60 to 1.34) | 0.89 (0.61 to 1.31) | 1.10 (0.73 to 1.66) | |||||
Significant values are indicated in bold characters.
*P values were based on χ2 test.
†P values were based on log-rank test for PFS and OS in the univariate analysis.
‡P values were bases on Wald test in the multivariate Cox proportional hazards regression model.
ICD, immunogenic cell death; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; SNP, single nucleotide polymorphism; TR, tumor response.